Current and Future Trends
Opioid use disorder (OUD) is a chronic disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs, and prolonged self-administration of opioid drugs. There are two subsets of patients who suffer from OUD: patients who become addicted to medical opioids, which are used to treat various pain conditions, and patients who become addicted to non-medical opioids, such as heroin, fentanyl, and fentanyl analogs.
The number of deaths caused by opioid overdoses has been steadily increasing over the last decade, most noticeably in the US, where the overuse of opioids is most significant.
Currently, there are a few drugs that are approved for the treatment of OUD, which can be split into two classes: synthetic opioid receptor agonists-buprenorphine and methadone-and opioid antagonists-naltrexone. These drugs have been widely available for decades, but many reformulations have been launched in recent years.
The markets included in this report are the countries that have the highest rates of opioid use; these are the US, Canada, Germany, Denmark, Belgium, Austria, Switzerland, and Australia.
In this webinar Maura Musciacco, Therapy Director at GlobalData, will present the changing OUD treatment landscape between 2017 and 2027, drawing on insights from GlobalData’s recently published report, Opioid Use Disorder (OUD) – Opportunity Analysis and Forecasts to 2027. The current treatment options and drug pipeline for OUD will be covered, including a discussion on GlobalData’s sales forecast for the OUD market. The webinar will include insights from KOLs covering the most important unmet needs for OUD, as well as the opportunities which are likely to remain by the end of the forecast period. Claire Herman, Global Director of Therapy Analysis and Epidemiology at GlobalData, will moderate a Q&A session following the presentation.
Presented by
Maura Musciacco,
Director, Neurology & Ophthalmology
Maura Musciacco, MSc, is the Director of Neurology and Ophthalmology at GlobalData in London. She has over a decade of experience in market analysis, business intelligence and providing strategic insight for the pharmaceutical industry. Prior to her current role, she was a Lead Analyst for Company Analysis at Datamonitor Healthcare, where she managed the portfolio and production of the team covering the top 40 pharmaceutical companies, in addition to being the in-house specialist for the orphan drug sector. Previously, she was an Analyst in the Strategy team at Datamonitor Healthcare, where she gained extensive experience writing in-depth reports covering various topics, including mergers and acquisitions, emerging markets, generics, and R&D trends. Maura started her career in market research, where she uncovered needs and trends in several therapeutic markets. She has an MSc in International Health Management from the Imperial College Business School, and a BSc in Molecular Biology from University College London (UCL).
Claire E. Herman,
Global Director of Therapy Analysis and Epidemiology
Claire Herman, MPH is Global Director of Therapy Analysis and Epidemiology at GlobalData in Boston. She has more than 15 years of experience in the healthcare industry, during which she has led teams in the development and delivery of industry-leading competitive intelligence product offerings. Claire began her career at Decision Resources, where she worked as an Analyst and Epidemiologist evaluating disease markets across therapeutic areas, assessing the potential of pipeline drugs in the context of current medical practice, and developing patient-based prescription drug sales forecasts. Prior to her current role, Claire was the Director of Autoimmune/Inflammation, CNS, and Ophthalmology for Citeline/Informa’s Trialtrove database, where she managed her team’s daily operations and was involved in various product enhancement initiatives. Previously, she was a Manager in Citeline’s consulting division, where she developed customized analyses of the clinical trials competitive landscape. Claire holds a Bachelor’s degree from Wellesley College and a Master of Public Health degree in epidemiology from Boston University.
